| Literature DB >> 36164296 |
Xifeng Fei1, Xiangtong Xie1, Xiaoyan Ji2, Haiyan Tian3, Fei Sun1, Dongyi Jiang1, Zhimin Wang1,4, Qiang Huang3.
Abstract
Distant metastasis is common in ocular uveal melanoma (uveal melanoma, UM) [1], with possible identification of relevant protein markers in peripheral blood [2], [3]. Proteomics analyses serve as a basis for the screening of new target proteins. However, it is difficult to determine whether the relevant proteins in peripheral blood are the same kinesins as those in primary lesions and metastases. Specially in this study, human UM cells (92.1) [4] were inoculated into the back of the eyeball and the brain of inbred line nude mice transplanted with enhanced green fluorescent protein (EGFP) [5], respectively, to simulate the growth of UM in situ and in brain metastases. A database was established as follows: Firstly, the xenograft was taken for monoclonal re-culture and amplification. Then, the cells after amplification (92.1-A in the back of the eyeball and 92.1-B in the brain) and their parent cells (92.1) were subjected to Tandem Mass Tag (TMT)-labeling proteomic analysis and liquid chromatography-mass spectrometry (LC-MS). Covering differential proteomes of three cell lines in a pairwise model, the data could be used to further screen the kinesins that play a vital role in regulating the growth of UM.Entities:
Keywords: Mass spectrometry-based quantitative proteomes; Monoclonal culture of transplantable tumor tissues; TMT-labeled HPLC; Uveal melanoma cells 92.1
Year: 2022 PMID: 36164296 PMCID: PMC9508510 DOI: 10.1016/j.dib.2022.108592
Source DB: PubMed Journal: Data Brief ISSN: 2352-3409
Fig. 1Differential protein expression. 302 and 335 proteins were downregulated and upregulated, respectively, in the 92.1-A/92.1 comparison group, and 160 and 129 proteins were downregulated and upregulated, respectively, in the 92.1-B/92.1 comparison group.
| Subject: | Cancer research |
| Specific subject area: | Screening of target molecules of uveal melanoma (UM) |
| Type of data: | Raw data storage |
| How data were acquired: | A quantitative proteomic analysis of melanoma was conducted via a combination of cutting-edge technologies, including Tandem Mass Tag (TMT) labeling, high-performance liquid chromatography (HPLC) classification technology, and the technology of mass spectrometry-based quantitative proteomics. |
| Data format: | Raw data |
| Parameters for data collection: | The 92.1 cell lines were obtained from the Eye and Ear Institute of the University of Pittsburgh Medical Center. The 92.1-B and 92.1-A cell lines were inoculated |
| Description of data collection: | There were 6081 proteins identified, among which 5267 carried quantitative data. Of all the quantified proteins, 302 and 335 proteins were downregulated and upregulated, respectively, in the 92.1-A/92.1 comparison group, provided a 1.2-fold change threshold and a standard of |
| Data source location: | Data were stored in the ProteomeXchange Consortium by virtue of the identifier PXD032215 of the PRIDE repository. |
| Data accessibility: | Name: PRIDE repository, Code: PXD032215, Link: |
| Related research article: | Xifeng Fei, Xiangtong Xie, Ruwei Qin, et al. Proteomics analysis: inhibiting the expression of P62 protein by chloroquine combined with dacarbazine can reduce the malignant progression of uveal melanoma. BMC Cancer. 2022 Apr 14;22(1):408. |